Suppr超能文献

采用酶切错配分析(ECMA)方案筛选人类基因中的微小改变。

Screening human genes for small alterations performing an enzymatic cleavage mismatched analysis (ECMA) protocol.

作者信息

Vogiatzakis Nikolaos, Kekou Kyriaki, Sophocleous Christalena, Kitsiou Sophia, Mavrou Ariadni, Bakoula Chrisa, Kanavakis Emmanouel

机构信息

Department of Medical Genetics, University of Athens, Athens, Greece.

出版信息

Mol Biotechnol. 2007 Nov;37(3):212-9. doi: 10.1007/s12033-007-0065-6. Epub 2007 Aug 3.

Abstract

Many human diseases are caused by small alterations in the genes and in the majority of cases sophisticated protocols are required for their detection. In this study we estimated the efficacy of an enzymatic protocol, which using a new mismatch-specific DNA plant endonuclease from celery (CEL family) recognizes and cleaves mismatched alleles between mutant and normal PCR products. The protocol was standardized on a variety of known mutations, in 11 patients with cystic fibrosis (CF), Fabry's disease (FD), steroid 21-hydroxylase deficiency (21-HD) and Duchenne/Becker muscular dystrophy (DMD/BMD). The method does not require special equipment, labeling or standardization for every PCR product, since conditions of heteroduplex formation and enzyme digestion are universal for all products. The results showed that the method is rapid, effective, safe, reliable, and very simple, as the mutations are visualized on agarose or nusieve/agarose gels. The protocol was furthermore evaluated in three DMD patients with the detection of three alterations which after sequencing, were characterized as disease causative mutations. The proposed assay, which was applied for the first time in a variety of monogenic disorders, indicates that point mutation identification is feasible in any conventional molecular lab even for cases, where other techniques have failed.

摘要

许多人类疾病是由基因的微小改变引起的,在大多数情况下,需要复杂的检测方案来检测这些疾病。在本研究中,我们评估了一种酶促检测方案的有效性,该方案使用一种来自芹菜的新型错配特异性DNA植物内切酶(CEL家族)来识别并切割突变型和正常PCR产物之间的错配等位基因。该方案在11例患有囊性纤维化(CF)、法布里病(FD)、类固醇21-羟化酶缺乏症(21-HD)和杜兴/贝克肌营养不良症(DMD/BMD)的患者中,针对多种已知突变进行了标准化。该方法不需要特殊设备、标记或针对每个PCR产物进行标准化,因为异源双链体形成和酶切条件对所有产物都是通用的。结果表明,该方法快速、有效、安全、可靠且非常简单,因为突变可在琼脂糖或低熔点琼脂糖/琼脂糖凝胶上可视化。此外,该方案在3例DMD患者中进行了评估,检测到3种改变,测序后将其鉴定为致病突变。首次应用于多种单基因疾病的该检测方法表明,即使在其他技术失败的情况下,在任何传统分子实验室中进行点突变鉴定都是可行的。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验